Introduction
============

Lung cancer is the worldwide leading cause of cancer death and the same is applied to Korea \[[@b1-crt-2018-366],[@b2-crt-2018-366]\]. Even with remarkable advancement in radiation therapy (RT) techniques and chemotherapy regimens, surgical resection still remains the choice of treatment for resectable non-small cell lung cancer (NSCLC) patients. However, the recurrence rates even following apparently complete curative resection have been reported as 25%-51% \[[@b3-crt-2018-366]-[@b7-crt-2018-366]\]. The post-recurrence prognosis has been generally poor, and the median survival duration following recurrence has been reported as 8.1-21 months in the previous literatures \[[@b4-crt-2018-366]-[@b6-crt-2018-366],[@b8-crt-2018-366]\], which largely depends on the recurrence site and subsequent therapeutic approach \[[@b8-crt-2018-366],[@b9-crt-2018-366]\]. In case of loco-regional recurrence (LRR), the local treatment modality including re-operation or high dose RT with or without concurrent chemotherapy would be considered, which could lead to for survival with local cure.

There have been a few studies on aggressive re-operation for resectable LRR or new primary lung cancer, most of which reported promising survival outcomes \[[@b10-crt-2018-366],[@b11-crt-2018-366]\]. Re-operation, however, can usually be limited only to the patients with adequate cardio-pulmonary functional reserves considering the risk of surgical morbidity and motality. The alternative option is high dose RT with or without concurrent chemotherapy. Several studies on salvage RT for LRR reported the rates of overall survival (OS) at 2 years ranging from 30% to 62.4% and the median survival ranging from 14 to 54.8 months \[[@b12-crt-2018-366]-[@b19-crt-2018-366]\]. Most of these studies included relatively small number of patients, with insufficient follow-up period. Their survival outcomes, however, were comparable to or even better than those of the patients who received radical RT as the initial therapy \[[@b20-crt-2018-366]-[@b22-crt-2018-366]\]. In addition, Bae et al. \[[@b15-crt-2018-366]\] previously demonstrated that the use of concurrent chemoradiation therapy (CCRT) was more favorable for OS over RT alone. Some other investigators also reported that salvage CCRT in treating the patients with LRR was promising \[[@b16-crt-2018-366],[@b18-crt-2018-366]\]. We would report the clinical outcomes and toxicity profiles following exclusively salvage CCRT in treating the patients who developed LRR following the initial curative complete resection.

Materials and Methods
=====================

1. Patients
-----------

We retrospectively reviewed the medical records of all patients who underwent salvage CCRT in the authors' hospitals between February 2004 and December 2016 for LRR of NSCLC following surgery. The decision on chemoradiotherapy, instead of surgical resection, was made through the multidisciplinary conference discussion, and all patients were presumed to have had high risk by reoperation considering the patients' condition, expected difficulty of resection, and risk of post-surgical morbidity. The inclusion criteria were (1) initial complete resection with or without adjuvant chemotherapy but without adjuvant RT, (2) no evidence of distant metastasis, and (3) CCRT with curative aim.

The suspicion and diagnosis of LRR was made in 127 patients, based on enlarging or new lesion on two or more consecutive chest computed tomography (CT), coupled with increased fluoro-deoxy-glucose uptake on positron emission tomography‒computed tomography (PET-CT). In principle, the diagnosis of LRR was to be made by cytopathological confirmation whenever possible, either by bronchoscopic or endobronchial ultrasound-guided needle biopsy and/or aspiration cytology, which was feasible in 80 patients (63.0%).

2. Treatment
------------

RT was given using 4-, 6-, or 10-MV photon beams from linear accelerators. The clinical target volume (CTV) was to cover the recurrent gross lesion(s) only with 5-10 mm margin in all directions but not to cover the regional lymphatics electively. Three-dimensional conformal RT using 3-4 beams was mainly used in 118 patients (92.9%) and intensity-modulated RT was used in nine (7.1%), who had relatively large CTV or poor lung function. The typical planned dose schedule was to deliver 66 Gy in 33 fractions, and the median total dose actually delivered was 66 Gy (range, 37 to 70 Gy). The median total dose converted into biologically equivalent dose (BED~10~) was 79.2 Gy~10~ (range, 44.9 to 84.8 Gy~10~).

Majority of patients (94.5%) were treated with weekly platinum-based doublet chemotherapy during the RT course and the chemotherapy regimens were weekly paclitaxel plus cisplatin in 68 patients (53.5%), weekly docetaxel plus cisplatin in 49 (38.6%), 3-weekly etoposide plus cisplatin in seven (5.5%), and weekly paclitaxel plus carboplatin in three (2.4%), respectively. The median number of weekly chemotherapy cycles was six (range, 2 to 7).

3. Endpoints and statistical analysis
-------------------------------------

The failure patterns following salvage CCRT were subdivided into in-field failure (IFF), out-of-field regional failure, and distant metastasis (DM): IFF was defined as the failure within the radiation field; out-of-field regional failure was defined as the failure in regional area out of radiation field; and DM was defined as failure in distant organs including parenchymal pulmonary metastasis, respectively. The end-points included the rates of IFF-free survival (IFFFS), locoregional failure-free survival (LRFFS), DM-free survival (DMFS), progression-free survival (PFS), and OS. The durations of IFFFS, LRFFS, DMFS, PFS, and OS were calculated from the date of start of RT to the date of the recurrence, death, or the last follow-up.

The chi-square test and t test were used to analyze the distributions of categorical and continuous variables, respectively.

The Kaplan-Meier method was used to determine the survival rate. The log-rank test was used to compare the differences between the groups, and the Cox proportional hazards regression model was used for multivariate analysis. A p-value less than 0.05 was considered statistically significant and the software SPSS ver. 23.0 (IBM Corp., Armonk, NY) was used for the statistical analysis.

4. Ethical statement
--------------------

This study was approved by the Samsung Medical Center Institutional Review Board (2018-03-160), and conducted in accordance with the principles of the Declaration of Helsinki. The informed consent was waived.

Results
=======

1. Patients' characteristics
----------------------------

The patients' characteristics are summarized in [Table 1](#t1-crt-2018-366){ref-type="table"}. The median age was 63 years (range, 37 to 79 years), and 79.5% of patients were male. Eastern Cooperative Oncology Group performance scores were 0 in 30 patients (23.6%), one in 91 (71.7%), and two in six (4.7%), respectively. The initial types of surgery were pneumonectomy in 11 patients (8.7%), lobectomy in 110 (86.6%), and sublobar resection in six (4.7%), respectively. The pathologic stages following the initial surgery according to American Joint Cancer Committee (AJCC) eighth stages were I in 37 patients (29.1%), II in 49 (38.6%), IIIa in 33 (26.0%), IIIb-c in five (3.9%), and unknown in three (2.4%), who underwent the initial surgery at other hospital, respectively. Adenocarcinoma and squamous cell carcinoma were the most common histological types observed in 72 (56.7%) and 48 patients (37.8%), respectively, and others were pleomorphic carcinoma in four, large cell carcinoma in one, adeno-squamous cell carcinoma in one, and combined squamous cell carcinoma with large cell carcinoma in one, respectively. The median disease-free interval (DFI), defined as the time from the initial surgery till the start of salvage CCRT was 15 months (range, 1 to 80 months). LRR following the initial surgery was subdivided into local, defined as the recurrence within or around the primary tumor, regional, as the recurrence within regional lymphatics, and loco-regional, as the recurrence including both local and regional recurrence components, respectively. The patterns of LRR were local in 21 patients (16.5%), regional in 81 (63.8%), and loco-regional in 25 (19.7%), respectively. All patients were re-staged as if they had been newly diagnosed as having NSCLC according to the AJCC eighth stage, and the recurrent stages were rI in nine patients (7.1%), rII in 12 (9.4%), rIIIa in 57 (44.9%), rIIIb in 48 (37.8%), and rIIIc in one (0.8%), respectively.

2. Survival outcomes
--------------------

The median follow-up time from the start of salvage CCRT in all patients was 25.0 months (range, 1 to 112 months). The median survival duration was 49 months and the 2- and 5-year OS rates were 72.9% and 43.9%, respectively ([Fig. 1A](#f1-crt-2018-366){ref-type="fig"}). On the univariate analysis, the favorable factors with OS were DFI longer than 1 year (p=0.009), BED~10~ higher than 79.2 Gy~10~ (p=0.012), and CTV smaller than 80 cm^3^ (p=0.001), respectively ([Table 2](#t2-crt-2018-366){ref-type="table"}). Multivariate Cox regression analysis of the possible favorable prognostic factors for OS were higher BED~10~ (≥ 79.2 Gy~10~ vs. \< 79.2 Gy~10~; hazard ratio \[HR\], 0.431; 95% confidence interval \[CI\], 0.238 to 0.781; p=0.005), smaller CTV (≤ 80 cm^3^ vs. \> 80 cm^3^; HR, 0.403; 95% CI, 0.215 to 0.755; p=0.005), and longer DFI (\> 1 year vs. ≤ 1 year; HR 0.489; 95% CI, 0.277 to 0.864; p=0.014), respectively.

3. Failure pattetns following salvage CCRT
------------------------------------------

The 2- and 5-year rates of IFFFS, LRFFS, DMFS, and PFS were 82.4% and 73.8%, 59.8% and 51.4%, 50.4% and 39.9%, and 34.6% and 22.3%, respectively ([Fig. 1B](#f1-crt-2018-366){ref-type="fig"}). Eighty patients (63.0%) experienced further recurrence following salvage CCRT. [Fig. 2](#f2-crt-2018-366){ref-type="fig"} presents failure patterns in relation to RT target volume. Twenty patients (15.7%) developed IFF; 38 (29.9%) did out-of-field regional failure; and 60 (47.2%) did DM, respectively. The BED~10~ higher than 79.2 Gy~10~ was the only statistically significant factor for PFS (p=0.043) on the univariate analysis ([Table 2](#t2-crt-2018-366){ref-type="table"}), and showed marginal significance on multivariate Cox regression analysis (≥ 79.2 Gy~10~ vs. \< 79.2 Gy~10~; HR, 0.597; 95% CI, 0.354 to 1.005; p=0.052).

4. Toxicity
-----------

Though seven patients (5.5%) could not complete the initially planned treatment mostly due to appearance of unexpected acute events including esophagitis, pneumonia, and worsening general condition, there was no incidence of grade 4 or 5 toxicity, and most patients tolerated salvage CCRT very well. The radiation-induced esophagitis was the most common acute toxicity and grade 2-3 esophagitis occurred in 57 (44.9%) and 14 patients (11.0%), respectively. Grade 2 and 3 delayed radiation pneumonitis occurred in eight (6.3%) and six patients (4.7%), respecetively. Other rare toxicities included grade 2-3 radiation dermititis in four (3.2%) and grade 3 bronchial obstruction in one (0.8%), respectively ([Table 3](#t3-crt-2018-366){ref-type="table"}).

Discussion
==========

In treating the patients with locally advanced NSCLC, the fact that CCRT could significantly improve OS and PFS, when compared to RT alone, has been confirmed by several randomized trials and systematic reviews \[[@b20-crt-2018-366],[@b21-crt-2018-366]\]. Meanwhile, it has not been properly studied whether OS benefit can be achieved by CCRT when compared with RT alone in salvage therapy setting. Instead, there have been a few studies, which advocated CCRT over RT alone by demonstrating improved clinical outcomes \[[@b15-crt-2018-366]-[@b16-crt-2018-366],[@b18-crt-2018-366]\]. Bae et al. \[[@b15-crt-2018-366]\] of authors' institution previously reported the clinical outcomes of patients with LRR who received salvage RT, in which the proportion of patients receiving concurrent chemotherapy was only 21.9%. The 2-year rates of IFFFS and OS were 52.3% and 47.9%, respectively, and it was shown that CCRT could improve the 2-year OS rate significantly when compared with RT alone (65.2% vs. 43.5%, p=0.029 by univariate analysis, and p=0.038 by multivariate analysis). The present study which focused only to the 127 patients treated with CCRT, of the largest in number until as of yet, indicated that improved clinical outcomes (the 2-year rates of IFFFS and OS of 82.4% and 72.9%, respectively), when compared with the previous reports ([Table 4](#t4-crt-2018-366){ref-type="table"}).

Bae et al. \[[@b15-crt-2018-366]\] also pointed out that the use of PET-CT in diagnosing LRR, though not statistically significant, could reduce the time delay before treatment initiation and subsequently improve survival. PET-CT is well known to have improved the accuracy of diagnosis and stage assignment and subsequently clinical outcomes by assissting the therapeutic decision in lung cancer \[[@b22-crt-2018-366]-[@b25-crt-2018-366]\]. Jimenez-Bonilla et al. \[[@b26-crt-2018-366]\] also reported that PET-CT was highly accurate in detection of LRR and favorably affected survival. In this study, though cyto-pathological confirmation of LRR was feasible in less than two-thirds of the patients (63.0%), all patients were diagnosed as having LRR based on the serial CT changes coupled with abnormality on PET-CT. Furthermore, most patients after salvage CCRT, were monitored with chest CT and PET-CT, which might have allowed early detection of further relapse and rapid decision making for the subsequent salvage effort. The improved clinical outcomes in the current study could have resulted from the broad use of PET-CT as well as efficacy of CCRT.

In patients with pathologic III and margin negative NSCLC, adjuvant chemotherapy has been the standard treatment option. Especially in pathological N2 patients, sequential chemoradiation therapy could be recommended to improve locoregional control. However, adjuvant chemotherapy or RT is often omitted if the patients were with poor postsurgical condition or at old age, considering the increased risk of morbidity. In this study, all patients who developed locoregional recurrence following adjuvant RT following surgery were excluded, and among 38 patients who were with initial pathologic stage III, eight (21.1%) did not receive adjuvant chemotherapy. The reasons for not receiving chemotherapy, regardless of post-surgical recommendation, included the physicians' choice considering the patients' condition or age and the patients' refusal. Considering very poor post-recurrence prognosis in this group, the current study indicated that salvage CCRT, as the second curative attempt, could result in the improved survival outcome.

It is well known that the probability of local control and morbidity following RT mostly depens on the sensitivity to radiation, disease extent represented as the CTV, and its location in relation to the surrounding dose-limiting organs \[[@b27-crt-2018-366]-[@b30-crt-2018-366]\]. Lee et al. \[[@b17-crt-2018-366]\] reported that the gross tumor volume (GTV) was a prognostic factor for survival: the patients with GTV \< 20 cm^3^ had significantly higher OS rates than those with GTV \> 80 cm^3^. The size of recurrent lymph node by Seol et al. \[[@b19-crt-2018-366]\] and the single site recurrence by Kim et al. \[[@b18-crt-2018-366]\] were also proposed as the favorable factors for OS. In the current study, CTV \< 80 cm^3^ was proved a favorable factor for OS by both univariate and multivariate analyses. Though it is not easy to define the cut-off value on the GTV, it has been re-confirmed that the small disease extent is favorable factor following CCRT in the current study.

Synergy by concurrent delivery of radiation with chemotherapy is capable of achieving high rate of local control, however, should be cautiously used because of more frequent and severe toxicity profiles, when compared with single modality alone. The systematic reviews on CCRT in locally advanced NSCLC reported more treatment-related deaths (4% vs. 2%) and significantly more common severe esophagitis (risk ratio, 4.96; 95% CI, 2.17 to 11.37) following CCRT \[[@b21-crt-2018-366]\]. In this study, radiation target volume was to cover the recurrent lesions only with margin without elective nodal irradiation considering the toxicities to adjacent organs. Loco-regional failures developed in 47 patients (37%), and 2-year rates of PFS and LRFFS were 34.6% and 59.8%, respectively. These profiles were comparable with those of the prior studies that reported 2- or 3-year rates of PFS ranging from 33.6% to 44.9%, and LRFFS from 57.6% to 70.9% \[[@b17-crt-2018-366],[@b18-crt-2018-366]\]. Meanwhile, there was occurrence of neither severe chronic toxicity nor treatment-related death. The most commonly reported complications in salvage treatment setting are radiation-induced esophagitis and pneumonitis. The incidences of radiation-induced esophagitis and pneumonitis of Common Terminology Criteria for Adverse Event (CTCAE) grade ≥ 2 were reported in the range of 28.9%-41.9% and 16.1%-24.6% \[[@b17-crt-2018-366]-[@b19-crt-2018-366]\] in the previous studies. In the present study, the incidence of acute radiation-induced esophagitis of CTCAE grade ≥ 2 was relatively high as 55.9%, which might be affected by that all patients in this study had been treated with CCRT. However, that of grade ≥ 3 was 11.0%, which was comparable with others (0%-16.7%) \[[@b15-crt-2018-366]-[@b19-crt-2018-366]\]. The incidence of radiation pneumonitis of CTCAE grade ≥ 2 in the current study was 11.0% and was comparable those of other studies. Based on these toxicity profiles, salvage CCRT, with the policy of limited target volume, were judged quite tolerable. However, efforts to further reduce the toxicity risk might be warranted, considering most patients might already have impaired lung function and performance status following the initial surgery.

In conclusion, the current study has demonstrated that high dose salvage CCRT focused to the involved lesion only was highly effective and safe. In particular higher BED~10~, smaller CTV, and longer DFI were favorable factors for improved survival.

Conflict of interest relevant to this article was not reported.
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###### 

Patients' characteristics

  Variable                                                                      No. of patients
  ----------------------------------------------------------------------------- -----------------
  **Age (yr)**                                                                  63 (37-79)
  **Sex**                                                                       
   Male                                                                         101 (79.5)
   Female                                                                       26 (20.5)
  **ECOG performance status**                                                   
   0                                                                            30 (23.6)
   1                                                                            91 (71.7)
   2                                                                            6 (4.7)
  **Initial type of surgery**                                                   
   Pneumonectomy                                                                11 (8.7)
   Lobectomy                                                                    110 (86.6)
   Sublobar resection                                                           6 (4.7)
  **Initial pathologic stage^[a)](#tfn1-crt-2018-366){ref-type="table-fn"}^**   
   I                                                                            37 (29.1)
   II                                                                           49 (38.6)
   IIIa                                                                         33 (26.0)
   IIIb-c                                                                       5 (3.9)
   Unknown                                                                      3 (2.4)
  **Histology**                                                                 
   Adenocarcinoma                                                               72 (56.7)
   Squamous cell carcinoma                                                      48 (37.8)
   Others                                                                       7 (5.5)
  **Recurrent stage^[a)](#tfn1-crt-2018-366){ref-type="table-fn"}^**            
   rI                                                                           9 (7.1)
   rII                                                                          12 (9.4)
   rIIIa                                                                        57 (44.9)
   rIIIb-c                                                                      49 (38.6)
  **Disease-free interval (yr)**                                                
   \> 1                                                                         73 (57.5)
   ≤ 1                                                                          54 (42.5)

Values are presented as median (range) or number (%).

ECOG, Eastern Cooperative Oncology Group.

Stage according to American Joint Cancer Committee eighth edition.

###### 

Prognostic factors for 2-year rates of OS and PFS

                                                                                No. of patients   2-Year OS (%)   p-value   2-Year PFS (%)   p-value
  ----------------------------------------------------------------------------- ----------------- --------------- --------- ---------------- ---------
  **Age (yr)**                                                                                                                               
   ≤ 63                                                                         64                72.9            0.392     29.8             0.164
   \> 63                                                                        63                73.1                      39.6             
  **Sex**                                                                                                                                    
   Male                                                                         101               73.8            0.784     36.1             0.233
   Female                                                                       26                69.6                      29.8             
  **ECOG performance status**                                                                                                                
   0                                                                            30                88.5            0.161     31.3             0.529
   1                                                                            91                68.0                      35.2             
   2                                                                            6                 66.7                      50.0             
  **Initial type of surgery**                                                                                                                
   Pneumonectomy                                                                11                54.5            0.477     55.6             0.106
   Lobectomy                                                                    110               73.7                      31.2             
   Sublobar resection                                                           6                 100                       55.6             
  **Initial pathologic stage^[a)](#tfn2-crt-2018-366){ref-type="table-fn"}^**                                                                
   I                                                                            37                71.2            0.876     28.0             0.876
   II                                                                           49                77.3                      32.8             
   IIIa-c                                                                       38                64.6                      43.5             
   Unknown                                                                      3                 \-                        \-               
  **Recurrent stage^[a)](#tfn2-crt-2018-366){ref-type="table-fn"}^**                                                                         
   rI                                                                           9                 50.8            0.241     22.5             0.137
   rII                                                                          12                88.9                      56.6             
   rIIIa                                                                        57                77.5                      38.0             
   rIIIb-c                                                                      49                67.5                      28.0             
  **Disease-free interval (yr)**                                                                                                             
   \> 1                                                                         73                81.3            0.009     37.1             0.751
   ≤ 1                                                                          54                62.4                      31.4             
  **BED~10~ (Gy)**                                                                                                                           
   \< 79.2                                                                      25                57.6            0.012     10.4             0.043
   ≥ 79.2                                                                       102               76.7                      40.8             
  **Clinical target volume (cm^3^)**                                                                                                         
   ≤ 80                                                                         60                84.3            0.001     33.7             0.862
   \> 80                                                                        67                63.3                      35.2             

OS, overall survival; PFS, progression-free survival; ECOG, Eastern Cooperative Oncology Group; BED, biologically equivalent dose.

Stage according to American Joint Cancer Committee eighth staging system.

###### 

Treatment-related toxicity

  Adverse event                         Gr 0/1       Gr 2        Gr 3
  ------------------------------------- ------------ ----------- -----------
  Acute radiation-induced esophagitis   56 (44.1)    57 (44.9)   14 (11.0)
  Radiation pneumonitis                 113 (89.0)   8 (6.3)     6 (4.7)
  Radiation dermatitis                  7 (5.5)      3 (2.4)     1 (0.8)
  Bronchial obstruction                 0            0           1 (0.8)

Values are presented as number (%).

###### 

of salvage radiation therapy (RT) for loco-regional recurrent non-small cell lung cancer

  Study                                   Period      No.   RT dose, median (range, Gy)   Proportion of patients receiving CCRT (%)   OS at 2 yr (%)   Median OS (mo)
  --------------------------------------- ----------- ----- ----------------------------- ------------------------------------------- ---------------- ----------------
  Kelsey et al. \[[@b12-crt-2018-366]\]   1991-2003   29    66 (46-74)                    51.7                                        38               17
  Tada et al. \[[@b13-crt-2018-366]\]     1992-2002   31    60                            16.1                                        30               14
  Cai et al. \[[@b14-crt-2018-366]\]      1992-2004   54    \> 59.4                       47.8                                        14.8 (at 5 yr)   19.8
  Bae et al. \[[@b15-crt-2018-366]\]      1994-2007   64    54 (44-66)                    21.9                                        47.9             18.5
  Bar et al. \[[@b16-crt-2018-366]\]      1999-2009   30    63.5 (26-66)                  100                                         50.8             26.9
  Lee et al. \[[@b17-crt-2018-366]\]      2001-2009   38    60 (45-75)                    31.6                                        56               27.9
  Kim et al. \[[@b18-crt-2018-366]\]      2004-2014   57    66 (45-70)                    73.7                                        62.4             54.8
  Seol et al. \[[@b19-crt-2018-366]\]     2008-2013   31    66 (51-66)                    51.6                                        58.4             14
  Current study                           2004-2016   127   66 (37-70)                    100                                         72.9             49

CCRT, concurrent chemo-radiation therapy; OS, overall survival.
